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Netherlands FUO Imaging Group
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We studied the role of 111ln-labeled immunoglobulin (111ln-lgG) 
scintigraphy in different subgroups of patients with fever of unknown 
origin (FUO). Methods: During a 2-yr period (January 1992 through 
January 1994), the internal medicine wards of eight university 
hospitals in The Netherlands participated in this study. A total of 167 
patients with FUO were prospectively included to prevent unin­
tended selection. Fifty-eight patients underwent1111n-IgG scintigra­
phy. For 23 patients without potentially diagnostic clues (PDCs) or 
only misleading PDCs, the technique was used as a screening 
procedure. In 35 patients with PDCs pointing at local inflammation 
this technique was used when indicated. Results: After diagnostic 
work-up, infections were found in 17 patients (29%), neoplasms in 6 
(10%), noninfectious inflammatory diseases in 14 (24%) miscella­
neous disorders in 3 (5%) and no diagnosis in 18 (31%). Indium- 
111-lgG scintigraphy was helpful in the diagnostic process for 
patients with PDCs at local inflammation only. The diagnostic yield 
of this technique in this subgroup was 26%. Infection was found in 
only 10/41 patients with negative scans. All infections were nonfocal 
or located in the heart, liver region or urinary tract where physiolog­
ical uptake obscures possible pathologic uptake. The overall sensi­
tivity and specificity was 60% and 83%, respectively. Conclusion: 
In patients without PDCs for local inflammation, the diagnostic yield 
of scintigraphic techniques was quite low since no focal inflamma­
tion was observed. Therefore, 1111n-IgG scintigraphy should not be 
used as a second-step procedure in the work-up of these subgroup 
of patients with FUO. In patients with PDCs at local inflammation, 
1111n-IgG is helpful in the diagnostic process in one-fourth of the 
patients. This diagnostic yield is comparable with that of the majority 
of other scintigraphic techniques used in the diagnostic process of 
patients with FUO.
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Petersdorf and Beeson ( /)  defined fever of unknown origin 
(FUO) as a febrile illness evolving over at least 3 \vk. with 
documented temperature of at least 38.3°C ( I () I °F ) on three or 
more occasions and uncertain diagnosis after I wk of diagnostic 
work-up in the hospital.
Scintigraphic methods play an important role in the diagnos­
tic process of these patients as instruments to demonstrate or 
exclude local inflammatory and infectious diseases. Scinti­
graphic imaging with Ga, IMIn or i)i,mTc white blood cells 
(WBCs). MIIn labeled-immunoglobulin G ( m ln-IgG) and 
WmTc-labeled BW250/183, an antigranulocyte monoclonal an­
tibody of murine origin, has been applied in patients with FUO 
to detect inflammatory foci (2-7). Some investigators believe 
that scintigraphy should be a second step as apposed to a last 
resort procedure in the evaluation of FUO (2). However, the
diagnostic yield of scintigraphic methods in the diagnostic 
process of FUO is unknown, mainly because these previous 
studies were retrospective in nature.
We performed a prospective study on the utility of 11 1 In-IgG 
scintigraphy to ascertain the role and diagnostic yield of 
scintigraphy in patients with FUO without indices of inflam­
mation. Indium-11 1-lgG scintigraphy has proven to be a prom­
ising technique in FUO in that it has technical advantages over 
other scintigraphic techniques and high diagnostic accuracy 
( 6, 8 ) .
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MATERIALS AND METHODS 
Patients
From January 1992 through 1994, a prospective study on FUO, 
approved by all local ethical committees, w'as performed in all 
eight Dutch university hospitals. All immunocompetent patients 
fulfilling the classic criteria of FUO formulated by Petersdorf and 
Beeson (1) were entered into the study. All participants gave 
informed consent and 167 patients were included in our FUO 
protocol, which consisted of a standardized multiple choice history, 
physical examination and certain obligatory investigations (Table
1 ). Indium-111-lgG scintigraphy was performed in 58 of these 167 
patients (33 women. 25 men; age range 21-87 yr, mean 55 yr).
Much consideration was given to the presence or absence of 
potentially diagnostic clues (PDCs), defined as all localizing 
abnormalities potentially pointing towards a diagnosis and the use 
of these PDCs in the diagnostic process. Misleading PDCs were 
defined as PDCs not leading to the definite diagnose. All data, 
including those on PDCs, were prospectively registered in a 
structured data collection form. In the presence of PDCs. appro­
priate investigations were performed. In the absence of PDCs or in 
the presence of only misleading PDCs, patients underwent a two 
staged screening diagnostic protocol (Table 1) which included 
111 In-IgG scintigraphy in the first stage. This diagnostic protocol 
was discontinued when a definite diagnosis was made, PDCs 
appeared or fever subsided.
No PDCs or only misleading PDCs were present in 43 patients 
when prospectively studied. In these patients, the first stage of the 
diagnostic screening protocol was performed. Because this scinti­
graphic part of the study was not initiated until January 1993, only
23 of these 43 patients underwent m ln-IgG scintigraphy. In the 
remaining 124 patients with PDCs, m In-IgG scintigraphy was 
performed in 35 patients because of suspected localized inflamma­
tion based on PDCs. Both groups are evaluated separately in this 
study.
Exclusion criteria for m ln-IgG scintigraphy were agammaglob­
ulinemia, selective IgA deficiency and a history of severe adverse 
reactions after intravenous or intramuscular administration of 
human IgG. Pregnant or lactating women were also excluded from 
this study. None of the patients had uremia, but this was not an 
exclusion criterion.
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TABLE 1
Diagnostic Protocol
Investigations Performed in all Patients after Study Inclusion 
Sedimentation rate; hemoglobin; mean cellular volume; 
platelet count; leukocyte count and differential count; 
serum urea nitrogen; creatinine; sodium; potassium; protein; protein 
fractions;
alkaline phosphatase; aminotransferase; lactate dehydrogenase; creatine 
phosphokinase; 
antinuclear antibodies; rheumatoid factors; 
urinary analysis; faeces for occult blood;
blood cultures aerobic and anaerobic (three times); tuberculin test; 
urine-, feces-, and sputum culture when indicated; 
chest radiography; ultrasonography of upper abdomen
Phase 1 : Diagnostic Protocol in Patients without PDCs 
Pulse/temperature measurement with observer 
Fundoscopy by an ophthalmologist 
Calcium, phosphate, urate, amylase and TSH/T4 
Immunoelectrophoresis of serum and urine 
CRP, ACE, ANCA, anti-dsDNA, AST and cryoglobulin 
C3, C4, CH50 and circulating immune complexes 
Serology for Cytomegalovirus, Epstein-Barr virus, Mycoplasma, Brucella, 
Toxoplasma, Borrelia, Coxiella, Treponema and Yersinia 
Blood cultures for more than a week, stools for worms, eggs, cysts 
Blood, urine and gastric fluid cultures for tuberculosis 
Bone marrow puncture and culture on Mycobacteria, Brucella, Yersinia 
Indium-111 -IgG scintigraphy 
Radiography of teeth and sinus 
Ultrasound of lower abdomen
Phase 2: Diagnostic Protocol in Patients without PDCs 
Hepatitis B serology
Repeated PPD, when negative Merieux skin tests on anergy 
Repeated chest radiography 
IgD measurement
Liver biopsy and culture for Mycobacteria and other bacteria and fungi;
IF on Yersinia
Crista biopsy and culture on Mycobacteria, Brucella, bacteria; IF on 
Yersinia 
Ultrasound of the heart 
CT abdomen and thorax 
Colon radiography
Temporal artery biopsy if the patient is older than 55 yr
CRP = C-reactive protein; ACE = angiotensin converting enzyme; 
ANCA = antineutrophil cytoplasmatic antibody; AST = antistreptolysin titer; 
C = complement; CMV = cytomegalovirus; EBV = epstein-barr virus; IF = 
immunofluorescence; PPD = purified protein derivative.
When possible, the scintigraphic findings were verified micro- 
biologically but in some cases verification was made by clinical, 
radiographic and ultrasonographic methods. The final diagnosis 
and prospective analysis of diagnostic clues were made by one of 
the authors of this article and the attending physicians.
Radiopharmaceuticals
Human nonspecific polyclonal IgG conjugated to diethylenetri- 
aminepentaacetic bicyclic anhydride was prepared as a lyophilized 
kit for one step labeling with 11 'in according to the manufacturer’s 
instructions. A dose of 2 mg IgG labeled with 75 MBq of 11 'in was 
injected intravenously.
Imaging Procedures
Scintigraphic images were obtained with a gamma camera 
connected to an image processor. All images were collected in 
digital format in a 256 X 256 matrix. A medium-energy, parallel­
hole collimator was attached to the camera. Both " 1 In peaks of 173 
and 247 keV were used with 15% symmetric windows.
The '"In-IgG images were acquired 4, 24 and 48 hr after 
injection for a preset time of 5, 7.5 and 10 min, respectively. At 
least once, 24 hr after injection, spot views of the total body were 
obtained. All images were interpreted by two observers who were 
blinded to the results of the verification procedures. Disagreements 
were resolved by consensus.
An 111 In-IgG scan was interpreted as positive only if consistent, 
focally increasing accumulation could be observed over time. An
111 In-IgG scan was considered true-positive only when this imag­
ing procedure was considered helpful in the diagnosis.
Statistical Analysis
Differences between groups were analyzed using Fischer’s exact 
test and Mann-Whitney U-test or Student’s t-test.
RESULTS
Of the 58 patients who underwent 111 In-IgG scintigraphy, no 
diagnosis was established in 18 patients (31%), infection was 
found in 17 patients (29%), a neoplasm in 6 (10%), noninfec- 
tious inflammatory disease (NIID) in 14 patients (24%) and 
miscellaneous diseases in 3 (5%). For the following variables 
there were no significant differences between the group of 
patients with FUO who underwent m In-IgG scintigraphy (n =  
58) and those who did not (n =  109): percentage of patients 
with no diagnosis, duration of diagnostic process, period of 
follow-up, age, percentage of patients with periodic fever and 
duration of hospitalization.
Fourteen of 35 (40%) patients (Table 2) with PDCs had 
positive scans as compared to 3 of 23 (13%) patients (Table 3) 
who had undergone m In-IgG scintigraphy as a screening 
procedure (p =  0.04).
In patients with PDCs, m In-IgG scintigraphy helped estab­
lish the final diagnosis in 9 of 35 (26%) patients (Table 2, Figs.
1, 2 and 3), whereas it was not helpful diagnostically in 23 
patients (Table 3) who had the test as a screening procedure 
(p =  0.03).
In nine patients (16%), all patients with PDCs at local 
inflammation, m In-IgG scintigraphy was helpful in establish­
ing a diagnosis. In eight patients (14%), a positive m In-IgG 
scintigram did not lead to the final diagnosis. In two of these 
patients, clinically suspected arthritis was confirmed by the 
m In-IgG scintigraphy, and in one patient, activity in the 
maxillary sinus was confirmed radiographically. However, a 
malignant lymphoma proved to be the cause of the fever. In the 
five remaining patients, m In-IgG scintigraphy was false-posi- 
tive and resulted in several unnecessary tests. In one of the latter 
patients, focal activity was observed in the right iliosacral joint. 
Pathological abdominal activity was observed in two patients, 
in the right ankle in one patient and abnormal activity was 
observed in both lungs in the fifth patient. In four of these five 
patients, no definite diagnosis could be established.
The data on the 41 patients with negative 111 In-IgG scans are 
shown in Tables 2 and 3. In 14 of these patients, no diagnosis 
was established after extensive work-up. Overall follow-up 
after inclusion in the study varied from 33 to 1421 days (median 
834 days). For patients without diagnosis, follow-up after study 
inclusion ranged from 362-1400 days (median 1053 days). In 10 
patients, an infection was diagnosed. Urinary tract infections 
(n =  3), viral infections (n = 3), endocarditis, secondary 
syphilis, cholangitis due to sludge and chronic yersiniosis. 
Calculated overall sensitivity of u l In-IgG scintigraphy in this 
study was 60% with a specificity of 83%.
DISCUSSION
In this study, we prospectively studied the utility of 111 In-IgG 
scintigraphy in patients with FUO. Sixteen percent of the
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TABLE 2
Patient Characteristics of Indium-111 Scans Performed on Indication (n = 35)
Patient
no.
Age
(yr) Clinical data
Localization uptake 
1111n-IgG scan
Final diagnosis (follow- 
up from inclusion, d)
Additional investigations 
(plus obligatory investigations)
1 65 Abdominal pain, diarrhea
True-Positive Scans 
Colon area Diverticulitis Coloscopy, abdominal CT
2 24 Rattling with normal x-ray Right lung (Fig. 1) Pleural empyema CT, pleura puncture, course
3 26 Diffuse abdominal pain Right lower Right adnexitis Laparoscopy, culture, course
4 72 Diffuse abdominal pain
abdomen 
Ascending colon Diverticulitis Colon radiography, abdominal US
5 72 Cervix cancer, tumor US Low abdomen Pelvic abscess Laparotomy and culture
6 37 Pain wrist, sicca syndrome
(Fig. 2)
Left arm Granulomatous myositis Muscle biopsy
7 33 Gartner’s syndrome, abdominal pain Desmoid tumor Necrosis desmoid tumor Abdominal CT, negative culture
8 62 Anemia, vascular graft Colon Ischemic colitis Laparotomy
9 53 Heart murmur/S. aureus Hip (Fig. 3) Endocarditis, abscesses Echocardiography
10 48 Vasculitis, breast cancer, arthritis
Positive, Not Helpful Scans 
Many joints Small metastasis Protocol 1 plus 2*, lymph node biopsy
11 27 Abnormal liver biopsy, arthritis knee Knee Hepatitis C Serology, puncture knee
12 52 IBD in past, abscess thoracic wall Right iliosacral joint Relapse IBD MRI bony pelvis/2e coloscopy
13 69 Abdominal pain, diarrhea Ascending colon No diagnosis (362) Coloscopy, colon radiography cultures
14 46 Lymphoma neck, abscess liver biopsy Terminal ileum No diagnosis (1067) Protocol 1 plus 2*. no coloscopy
15 78 Cystitis, cryoglobulinemia, dizziness
Negative Scans 
No activity Mixed cryoglobulinemia No infections, cryoglobulines
16 65 Erythrocyturia, heart murmur No activity Mixed cryoglobulinemia, Biopsy kidney, cryoglobulines
17 77 Abnormal urinary analysis No activity
glomerulonephritis 
Urinary tract infections Third urine culture during antibiotics
18 87 Heart murmur, anemia, splenomegaly No activity Culture negative Echocardiography positive
19 67 Raynaud phenomena, valve disease No activity
endocarditis 
Drug fever Clinical course
20 30 Tropical travels, gonorrhea past No activity Secondary syphilis Serology, abdominal US/CT
21 42 Hematospermia, gonorrhea past No activity Recurrent prostatitis Clinical course, response therapy
22 68 Mexican travel/diarrhea, dysuria No activity Urinary tract infection Second urine culture/therapy typhus
23 70 Erythema nodosum, abdominal pain No activity Polymyalgia rheumatica Abdominal US/CT, course
24 64 Heart murmur, lung atelectasis No activity Endocarditis S. bovis Echocardiography/culture
25 65 Pain back, caries, breast cancer past No activity Temporal arteritis Protocol 1 plus 2* (temporal biopsy)
26 55 Tropical travel, pain, smelly urine No activity Chronic yersiniosis Protocol 1*, clinical course
27 31 Epididymitis, lesion spine MRI, rash No activity Nonclassifiable vasculitis Protocol 1 plus 2*, spine biopsy
28 21 Wound contact mud, heart murmur No activity Reiter’s syndrome Exclusion endocarditis, course
29 21 Yersinia abscess spleen, aneurysms No activity Polyangiitis syndrome Skin biopsy, thoracal DSA
30 39 Arthritis, heart murmur, urticaria No activity No diagnosis (1365) Protocol 1*, joint radiography, US heart
31 31 Spitz-Holter drain, cough, blood stools No activity No diagnosis (1113) Colon radiography, negative cultures
32 65 Heart murmur, hip prothesis No activity No diagnosis (1107) Echocardiography, course
33 57 Lung infiltrate, paraprotein, osteolysis No activity No diagnosis (1142) Protocol 1 plus 2*, bronchoscopy
34 32 Abdominal pain, polycystic ovarian disease No activity No diagnosis (854) US, coloscopy, laparoscopy
35 18 Abdominal pain, cough No activity No diagnosis (627) Protocol 1*, abdominal CT
‘See Table 1.
IBD = inflammatory bowel disease; ANA = antinuclear antibody; RA = rheumatoid arthritis; T4 = thyroxine; TSH = thyroid-stimulating hormone.
m  In-IgG scans were helpful in the diagnostic process. The 
percentage of scans helpful in the diagnostic process, as 
reported in literature, varied from 18% to 75% (Table 4), but in 
most studies the scintigraphic method was helpful in the 
diagnostic work-up in about one-quarter of the patients. This 
was also observed in our study, since 111 In-IgG scintigraphy 
had a diagnostic yield of 26% in a subgroup of 35 patients with 
PDC for local inflammation. The variation of diagnostic yield in 
literature probably depends on the degree of selection in the 
group of patients with FUO. All but one study w'as conducted 
retrospectively (2). Moreover, in most studies, a large percent­
age of postoperative patients were included.
No diagnosis could be made in 18/58 (31%) patients in our 
study. Our findings were similar to data presented in recent 
studies {9,10). In earlier studies, this percentage is even lower 
(111).
There are definitely some problems w'ith the calculation of 
sensitivity and specificity of scintigraphic techniques in patients 
with FUO. First, since a final diagnosis is not established in all 
patients undergoing scintigraphy, the interpretation of the re­
sults of this procedure is hampered due to a lack of a golden 
standard. When additional investigations are negative and long­
term follow-up does not reveal an infection in these patients, it 
is probably legitimate to presume that local inflammation is not 
the cause of fever in these patients. In 30% of patients in our 
study, no diagnosis could be made after a median follow-up of 
2.5 yr. Second, in the subgroup of patients without PDC, no 
local inflammatory processes were found causing FUO. Thus, 
neither true-positive scans nor false-negative were found, mak­
ing calculation of sensitivity and specificity impossible in this 
subgroup. Third, in patients with a negative scintigram, a 
variety of diseases were found that could not be diagnosed with
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TABLE 3
Patients Characteristics of Indium-111-lgG Scans Performed as Screening (n 23)
Patient Age 
no. (yr) Clinical data
Localization 
uptake 1111n-IgG 
scan
Final diagnosis 
(follow-up from inclusion, d)
Additional investigations 
(plus obligatory investigations)
Positive, Not Helpful Scans
36 70 None Malleolus lateralis No diagnosis (1169) Ankle radiography, bone biopsy negative
37 57 Heart murmur/negative echocardiography, Both lungs No diagnosis (1263) Ventilation/perfusion scan
dyspnea with negative chest x-ray, RA
38 52 Abdominal lymphadenopathy Paranasal sinuses Malignant lymphoma Sinus radiography, mucosal swelling
Negative Scans
39 37 Lymphadenopathy, erythema nodosa No activity No diagnosis (1400) Protocol 1*
40 38 Changed defecation/normal coloscopy No activity No diagnosis (1269) Protocol 1*
41 36 Cough, lymphadenopathy, splenomegaly No activity No diagnosis (1039) Protocol 1*
42 46 Arthralgia, redness skin joint No activity No diagnosis (999) Enteric radiography, coloscopy
43 67 Emphysema, liver function disturbance No activity No diagnosis (976) Culture, US, liver biopsy
44 62 Prosthetic valves, right heart failure No activity No diagnosis (948) Protocol 1 plus 2*
45 71 Lung lesion for 1 yr, thrombocytopenia No activity No diagnosis (868) Chest radiography, bone marrow biopsy
46 21 Lymphadenopathy, splenomegaly, hemolysis No activity No diagnosis (904) Protocol 1 plus 2*, hemolysis analysis
47 66 None No activity Mixed cryoglobulinemia Protocol 1*
48 64 Generalized lymphadenopathy No activity AILD Fourth lymph-node biopsy
49 25 Lymphadenopathy, abdominal pain No activity Takayasu’s disease Protocol 1 plus 2 \  laparoscopy
50 33 Unexplained abundant diarrhea No activity Factitious fever Proven laxative disuse
51 43 Urticaria, lymphadenopathy No activity Urticarial vasculitis Protocol 1 plus 2*, skin biopsy
52 58 Liver function disorder, skin lesions No activity Cholangitis/sludge Abdominal CT and US
53 29 Low back pain, diarrhea, iridocyclitis No activity Still’s disease Protocol 1 *, clinical course
54 55 Sarcoidosis past, rash, lymphocytosis No activity Cytomegalovirus infection Serology, ACE/chest x-ray
55 71 Urticarial vasculitis, monoclonal IgM No activity Schnitzler’s disease Protocol 1*, skin biopsy, course
56 42 Cardiac valve disease/negative US of heart, No activity Hodgkin’s disease Bone biopsy, histology spleen
abdominal lymphadenopathy
57 44 Hepatosplenomegaly, lymphocytosis No activity Cytomegalovirus infection Serology
58 65 Weight loss, dyspnea, heart failure, irregular No activity Hyperthyroidism T4 and TSH
heartbeat
*See Table 1.
AILD = angioimmunoblastic lymphoma; ANA = antinuclear antibody; IBD = inflammatory bowel disease; RA = rheumatoid arthritis; T4 = thyroxine;
TSH = thyroid-stimulating hormone.
m  In-IgG scintigraphy because lesions were present in organs 
with relatively high physiologic uptake, such as the liver, heart 
and urinary tract. Nonfocal infections such as viral infections 
could not be excluded by 111 In-IgG scintigraphy. Despite these 
limitations of the technique, a negative scan did rule out focal 
infection or inflammation with a high degree of certainty.
Similar to 67Ga, M1In-WBCs and " mTc-HMPAO-labeled 
WBCs, 111 In-IgG can be excreted in the bowel under physio­
logical conditions {5,12,13). However, such excretion was not 
significant and hardly interfered with adequate evaluation of 
possible abdominal infections or inflammation {14). We ob­
served in two patients only abnormal bowel activity. In six other 
patients, however, pathological activity in the abdomen led to 
the final diagnosis.
In contrast to Knockaert et al. (2), in our study the duration of 
hospitalization and diagnostic process of patients who under­
went scintigraphy was not significantly longer than in patients 
who did not undergo scintigraphy. We performed m In-IgG 
scintigraphy as a secondary step in the diagnostic protocol for 
patients without PDCs, w'hereas Knockaert et al. (2) scheduled 
fl7Ga scintigraphy as a third step or last resort procedure when 
the source of fever remained unknown. Naturally, in this latter 
category, the chance of reaching a diagnosis is lower.
By prospectively separating patients without PDCs from 
those with PDCs for local inflammation, we found a strikingly 
low diagnostic yield of this technique when using it as a 
screening procedure in patients with FUO. Therefore, scinti-
FIGURE 1. A 24-yr-old mentally disabled man presenting with fever and 
rattling respiration had a normal chest radiography. The 111ln-lgG scan 
shows abnormal activity in the right lung (posterior view). CT and pleural 
puncture proved pleural empyema caused by S. pneumoniae. After antibiotic 
therapy, fever and symptoms resolved (Patient 2).
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TABLE 4
Diagnostic Utility of Scintigraphic Techniques in FUO in Literature
FIGURE 2. Cervical carcinoma was diagnosed in this 72-yr-old woman. 
Surgery was unsuccessful and radiotherapy was administered. After 3 mo, 
fever and abdominal pain developed. Abdominal US revealed a tumor 
consistent with abnormal uptake in the lower abdomen on 1111n-IgG scintig­
raphy. Laparotomy and culture revealed a pelvic abscess caused by Pepto- 
coccus spp. After surgery and antibiotic therapy, she recovered and her fever 
resolved (Patient 5).
graphic imaging should not he a second step procedure in the 
diagnostic work-up of this subcategory of patients with FUO.
CONCLUSION
During a 2-yr period, w^ e prospectively investigated 167 
patients with FUO. Of these patients, 58 underwent 111 In-IgG
FIGURE 3. A 53-yr-old woman was referred from another hospital because 
of fever of more than 3 wk duration. She also had a painful hip. Blood cultures 
grew S. aureus and echocardiography revealed vegetations on the mitral 
valve. The 1111n-IgG scintigraphy revealed metastatic abscesses in hip femur, 
skull and chest. A culture of material obtained by puncture of the hip grew S. 
aureus. After antibiotic therapy, the patient underwent cardiosurgery for valve 
replacement. Thereafter, her fever disappeared (Patient 9).
Investigators No. Scan
% helpful 
scans 
patients
Habibian et al. (75) 22 67Ga 55
Hilson, Maisey (76) 67 67Ga 75
Schmidt et al. (4 ) 32 111ln-oxine WBCs 22
Syrjälä et al. (3) 68 111ln-oxine WBCs 28
Roddie et al. (5 ) 17 99mTc-HMPAO WBCs 24
Macsweeney et al. (77) 25 111 ln-tropolonate WBCs 24
Davies et al. (78) 28 111 ln-tropolonate WBCs 18
Kelly et al. (19) 28 111ln-oxine WBCs 21
Suga et al. (20) 36 67Ga 47
Becker et al. (7) 34 ""T c -a n ti NCA 24
Knockaert et al. (2) 145 67Ga 29
Present study 58 1111n-IgG 16
NCA = nonspecific cross-reacting antigen.
scintigraphy. These patients were prospectively separated in 
patients with or without PDCs. Overall sensitivity and speci­
ficity was 60% and 83%, respectively. In patients without PDCs 
for local inflammation, the diagnostic yield of scintigraphic 
techniques is quite low since no focal inflammation was 
observed. Therefore, 111 In-IgG scintigraphy should not be used 
as a second-step procedure in the work-up of these subgroup of 
patients with FUO. In patients with PDCs at local inflammation, 
m In-IgG is helpful in the diagnostic process in one-fourth of 
the patients. This diagnostic yield is comparable with that of the 
ma jority of other scintigraphic techniques used in the diagnostic 
process of patients with FUO.
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Optimization of Technetium-99m-Labeled PEG 
Liposomes to Image Focal Infection: Effects of 
Particle Size and Circulation Time
Otto C. Boerman, Wim J.G. Oyen, Louis van Bloois, Emile B. Koenders, Jos W.M. van der Meer, Frans Fî.M. Corstens 
and Gert Storni
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In previous studies we have shown that liposomes sterically stabi­
lized with polyethylene glycol (PEG), preferentially localize in infec­
tious and inflammatory foci. In this study, we further optimized the 
formulation of PEG liposomes for infection imaging in a rat model. 
Methods: The biodistribution and imaging characteristics of differ­
ent liposomal formulations labeled with 99mTc were determined in 
rats with S. aureus infection of the left calf muscle. The influence of 
liposomal size (mean diameter varying from 90 nm to 220 nm) as 
well as circulation time (modulated by inclusion of 0-10 mole% 
phosphatidylserine) were studied. Results: The smallest liposomes 
displayed improved characteristics for infection imaging: 90-nm 
liposomes revealed the highest abscess uptake (1.6% ±  0.4% ID/g,
24 hr postinjection) in combination with the lowest splenic accumu­
lation (6.9% ±  0.7% ID/g, 24 hr postinjection) as compared to the 
larger sized preparations. Enhanced abscess-to-blood ratios (4.0 
versus 1.3 at 24 hr postinjection) were obtained by including 1.0 
mole% phosphatidylserine in the lipid bilayer of the PEG liposomes. 
However, enhanced blood clearance of these liposomes reduced 
their absolute abscess uptake. Conclusion: These results indicate 
that the in vivo behavior of PEG liposomes can be modulated to 
optimize their characteristics for infection imaging.
Key Words: PEGylated liposomes; sterically stabilized liposomes; 
S. aureus infection
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L ip o so m e s  are microscopic lipid vesicles consisting of one or 
more concentric lipid bilayers enclosing discrete aqueous 
spaces. Liposomes have been investigated extensively as carri­
ers for drugs in attempts to achieve selective deposition and/or 
controlled release of the encapsulated contents (7-5). In addi­
tion, liposomes have been tested as vehicles to image infection 
and inflammation (6,7). However, conventional liposomes are 
rapidly taken up by cells of the mononuclear phagocyte system 
(MPS), which are primarily located in the liver and spleen (8,9). 
A decade ago, one of the major goals in liposome research was
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to enhance their circulatory residence time to allow enhanced 
targeting to non-MPS tissues. It has been demonstrated that 
small, neutral, cholesterol-rich liposomes composed of rigid 
phospholipids of high-phase transition temperature show pro­
longed circulation times at relatively high lipid doses (10-12). 
More recently, it was demonstrated that inclusion of polyeth- 
yleneglycol (PEG), conjugated to phosphatidylethanolamine in 
the bilayer increased the blood circulation time as well (13,14). 
This increment was at least as large as that observed with the 
rigid lipid composition but without the requirements of specific 
lipid composition, particle size and lipid dose (15-17). The 
prolonged circulation time of PEG liposomes, also referred to as 
sterically stabilized or StealthK liposomes (Sequus Pharmaceu­
ticals Inc., Menlo Park, CA), is caused by reduced recognition 
by the MPS, as reflected by delayed and diminished hepatic and 
splenic accumulation. The development of long-circulating 
liposomal formulations has offered several new applications for 
liposomes such as; (a) long-term controlled release of drugs in 
the circulation; (b) improved antibody-guided delivery of lipo­
somes; and (c) enhanced targeting to non-MPS-related patho­
logical sites such as tumors and inflammatory foci (18,19).
Our previous studies in rats have shown that PEG liposomes 
labeled with either 11'in or " mTc may be excellent radiophar­
maceuticals for imaging infectious and inflammatory foci (1,2). 
The aim of this study was to tailor the PEG-liposomal formu­
lation for scintigraphic application in rats with focal S. aureus 
infection. The PEG-liposomal formulation we used in our 
previous studies was originally developed for controlled deliv­
ery of chemotherapeutics (15,20,21). In this study, we modified 
the size and lipid composition of the liposomes to optimize their 
in vivo behavior for imaging infection. Different liposome 
dispersions with a narrow size distribution were produced 
(mean size: 90, 120, 160 and 220 nm) and evaluated in vivo. In 
addition, the effects of enhanced blood clearance were investi­
gated by incorporating increasing amounts of phosphatidylser­
ine (PS) (0, 1 and 10 mole%) in the lipid bilayer. It has been 
shown that PS exposure strongly increases the recognition of 
PEG liposomes by macrophages, thereby causing enhanced 
blood clearance (22,23).
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